BioXcel Therapeutics (BTAI)
(Real Time Quote from BATS)
$0.61 USD
-0.03 (-3.97%)
Updated Aug 30, 2024 01:34 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
BTAI 0.61 -0.03(-3.97%)
Will BTAI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BTAI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BTAI
BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates
BTAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BTAI
Bioxcel Therapeutics (BTAI) Receives a Hold from Mizuho Securities
BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript
Buy Rating Maintained for Bioxcel Therapeutics Amid Positive Performance and Growth Prospects
BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
BioXcel Therapeutics price target lowered by $3 at H.C. Wainwright, here's why